Value of CA 15:3 in the follow-up of breast cancer patients.


CA 15:3, a new tumour marker detectable by two monoclonal antibodies (115 D 8 and DF 3), was measured by an immunoradiometric technique on the ELSA solid phase. Sixteen percent of patients with localized breast cancer had CA 15:3 levels greater than 25 U ml-1, and levels increased with tumour size. CA 15:3 levels greater than 25 U ml-1 were found in 54% of… (More)
DOI: 10.1038/bjc.1987.115

4 Figures and Tables


  • Presentations referencing similar topics